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Abstract
Background: A growing body of research suggests that elevated circulating levels of glucose and insulin
accelerate risk factors for a wide range of disorders. Low-risk interventions that could suppress glucose without
raising insulin levels could offer significant long-term health benefits.
Methods: To address this issue, we conducted two sequential studies, the first with two phases. In the first phase
of Study 1, baseline fasting blood glucose was measured in 20 subjects who consumed 70 grams of sucrose in
water and subsequently completed capillary glucose measurements at 30, 45, 60 and 90 minutes (Control). On day-
2 the same procedure was followed, but with subjects simultaneously consuming a novel formula containing l-
arabinose and a trivalent patented food source of chromium (LA-Cr) (Treatment). The presence or absence of the
LA-Cr was blinded to the subjects and testing technician. Comparisons of changes from baseline were made
between Control and Treatment periods. In the second phase of Study 1, 10 subjects selected from the original 20
competed baseline measures of body composition (DXA), a 43-blood chemistry panel and a Quality of Life
Inventory. These subjects subsequently took LA-Cr daily for 4 weeks completing daily tracking forms and repeating
the baseline capillary tests at the end of each of the four weeks. In Study 2, the same procedures used in the first
phase were repeated for 50 subjects, but with added circulating insulin measurements at 30 and 60 minutes from
baseline.
Results: In both studies, as compared to Control, the Treatment group had significantly lower glucose responses
for all four testing times (AUC = P < 0.0001). Additionally, the Treatment was significantly more effective in
lowering circulating insulin after 60 minutes from baseline (AUC = P = < 0.01). No adverse effects were found after
acute sucrose challenge or in those who consumed LA-Cr daily for four weeks.
Conclusions: As compared to a placebo control, consumption of a LA-Cr formula after a 70-gram sucrose
challenge was effective in safely lowering both circulating glucose and insulin levels.
Trial Registration: Clinical Trials.gov, NCT0110743
Background
A growing body of research suggests that elevated circu-
lating levels of glucose and insulin accelerate risk factors
for a wide range of pathological disorders [1-4]. Accord-
ingly, interventions with low-risk dietary supplements
that suppress glucose levels without raising insulin levels
could offer significant long-term health benefits [5]. Ani-
mal studies and a single clinical trial previously reported
that consumption of l-arabinose (LA), a poorly-
absorbed, readily-available sweet-tasting pentose sugar,
led to significant suppression of the circulating glucose
and insulin after sucrose challenge [6-8]. This appears
to be related to l-arabinose’s ability to lessen the rapid
absorption of sucrose typically found inmodern diets
thereby preventing elevation of circulating levels of glu-
cose and insulin [5] typically found in modern diets.
Similarly, other animal and human studies have also
reported suppression of circulating glucose levels with-
out elevating insulin with the consumption of various
forms of chromium (Cr) [9-13]. This appears to be* Correspondence: grk@ihtglobal.com
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related to chromium’s ability to enhance insulin sensitiv-
ity. The purpose of this study was to examine the effects
of a formula containing l- arabinose and trivalent chro-
mium (LA-Cr) on circulating glucose and insulin
responses to sucrose challenge.
Methods
All subjects gave written informed consent in compli-
ance with the Helsinki Declaration as approved by the
researchers’ ethics committee.
Study 1, Phase 1
A total of 20 non-diabetic subjects were enrolled in this
phase from a pool of subjects who had participated in
previous studies and had demonstrated a high compli-
ance with study protocols. Their relevant characteristics
are set out in Table 1. All 20 completed a DXA total
body composition scan, the 50-item Quality of Life
(QOL) inventory shown in Table 2 and the 43-chemistry
blood test panel shown in Table 3. Blood chemistries
were drawn at a Quest service Center of the subject’s
choice http://www.quest.com.
On test day-1 (Control), after fasting for 10 hours,
subjects completed a baseline “finger-stick” capillary
blood sample, and consumed 70 grams of sugar dis-
solved in 150 grams of bottled water. Blood glucose
levels were retested at 30, 45, 60 and 90 minutes. On
test day 2 (Treatment), subjects followed the same pro-
cedure, but with a LA-Cr supplement containing 1,000
mg of l-arabinose and 200 mcg of a patented food-
source chromium. All glucose measurements were obtained on-site using a glucometer (ACCU-CHEK
Aviva meter, ACCU-CHEK Multiclix, and Multiclix Pen,
Roche Diagnostics, Indianapolis IN).
For each subject and each timed test period, a change
from baseline was obtained by subtracting the values for
the corresponding baseline from the values of the four
test periods. A glucose “suppression score” was obtained
for each subject by subtracting the treatment change
score from the control change score. The suppression
scores were averaged over the 20 subjects and the
changes from control scores to treatment scores were
expressed as a percentage of control scores. Decreases
were shown as negative percentages. The area under the
curve (AUC) scores were obtained by using Kaleida-
Graph, graphing and data analysis, Version 3.6. The
AUC scores for glucose treatment periods for each sub-
ject were compared to the control AUC scores for each
subject using a paired, 2-tailed t-test. Significance was
defined as P < 0.05.
Study 1, Phase 2
Ten of the 20 subjects were randomly chosen and asked
to consume a daily serving of LA-Cr for four weeks.
Subjects provided daily tracking information on adverse
Table 1 Baseline demographics for Study 1, Phases 1 and






Number Subjects 20 10 50
Males 6 3 20
Females 14 7 30
Blacks 2 1 11
Hispanics 3 2 12
Whites 4 7 25
0 0 2
Mean SD Mean SD Mean SD
Age 53.8 11.3 53.7 11.8 40.2 14.8
Weight 195.8 46.8 195.8 48.1 182.2 44.8
Height 67.3 4.1 67.3 4.2 65.8 4.4
BMI 29.9 6.0 30.2 6.1 29.6 6.0
Bone Mineral Density 1.189 0.102 1.189 0.104 1.202 0.092
% Body Fat 42.4% 7.8% 42.4% 8.1% 38.9% 9.4%
Fat Mass 83.0 22.3 83.0 22.9 70.9 28.8
Fat-free Mass 112.8 35.6 112.8 36.6 111.3 27.4
Table 2 Quality of Life Inventory
1 Headaches 26 Irregular heartbeat
2 Irritable bowel syndrome 27 Shortness of breath
3 Arthritis 28 Constipation
4 Premenstrual syndrome 29 Stomach gas or indigestion
5 Recurring sinus infections 30 Feeling weak
6 Tension fatigue syndrome 31 Eating too rapidly
7 Recurrent anxiety 32 Eating after being full
8 Recurrent depression 33 Embarrassed about overeating
9 Insomnia 34 Depressed over eating habits
10 Low self esteem 35 Depressed about my weight
11 Binge eating 36 Difficult to stop eating
12 Chronic tension 37 Worrying about the future
13 Lack of energy 38 Unable to concentrate
14 Food allergies 39 Forgetfulness
15 Feeling under stress 40 Bad temper or quick to anger
16 Cancer 41 Indigestion
17 Prostate problems 42 Diabetes
18 Overeating 43 Vomiting
19 Stomach pain 44 Heartburn
20 Back pain 45 Esophageal reflux
21 Pain in arms, legs, or joints 46 Control over my appetite
22 Menstrual pain or problems 47 Ability to relax
23 Chest pain 48 Heart disease
24 Dizziness 49 Fibromyalgia
25 Diarrhea 50 Difficulty in falling asleep
Subjects Rated Magnitude of Problems Occurring Over the last
30 Days Using a Scale of 0 = None, 1 = Minor, 2 = Major and 3 = Severe
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effects. At the conclusion of each week, subjects com-
pleted the same Treatment sucrose challenge as
described in Phase 1 and repeated the Blood, DXA, and
QOL inventory at the end of the 4th week.
Study 2
Fifty new non-diabetic subjects were recruited, and
completed the same DXA and QOL inventory used in
phase 2 of Study 1. In addition to glucose measure-
ments, fasting insulin measurements were also obtained
at baseline, 30 and 60 minutes from baseline with and
without simultaneous consumption of the LA-Cr sup-
plement at baseline. Insulin measurements were per-
formed by Quest Laboratories, San Antonio, TX. The
same procedures and instruments used in the pilot
study were used to obtain glucose and insulin suppres-
sion scores. Significance was defined as P < 0.05. All 50
subjects completed the glucose measurements. The
phlebotomist was unable to draw blood from one sub-
ject and accordingly 49 subjects completed the insulin
tests. To examine the relationship between the total glu-
cose suppression or the total insulin suppression and
baseline factors, each suppression score was compared
with each baseline factor as follows: The data were
ranked in order of suppression score and separated into
quartiles, with Q1 representing the most suppression
and Q4 representing the least suppression. An analysis
of variance (ANOVA) was conducted across the 4 quar-
tiles. Significance was defined as P < 0.05.
Results
The data for each of the groups and each of the time
periods are shown in Table 4. As shown in Table 5,
consuming La-Cr simultaneously with a 70 gram
sucrose challenge (treatment) suppressed the glucose
response in both Study 1 and 2 in all four time mea-
surements as compared to control. These differences
were statistically significant for all four time periods.
Circulating insulin levels were also statistically lower at
60 minutes in the treatment group. Although not
shown, weekly reductions in glucose were essentially the
same in each of the four weeks as were found for these
subjects in the first phase of Study 1. In addition, no sig-
nificant changes were found in comparisons between
baseline and ending blood chemistries and self-reported
QOL scores.
To further examine the association between suppres-
sion scores and baseline measures, glucose and insulin
suppression scores were divided into four equal quar-
tiles. An ANOVA revealed that there were no statisti-
cally significant relationships between glucose
suppression scores and baseline measures of glucose,
insulin, age, gender, ethnicity, scale weight, height, bone
mineral density, total body fat, total body lean, and body
mass index. However, there was a significant association
between glucose suppression scores and % body fat (P =
0.038). A further comparison of the quartiles of glucose
suppression scores and % body fat revealed that the
greater the suppression score, the lower the % body fat
(Q4 = 42.5%, Q3 = 40.8%, Q2 = 40.0%, Q1 = 32.5%). A
Student t-test between the highest (n = 12) and lowest
(n = 12) glucose suppression quartiles was also signifi-
cant (P = 0.025).
Discussion
This study compared the acute effects of the simulta-
neous ingestion of a combined l-arabinose and trivalent
chromium formulation (LA-Cr) after a 70 gram oral
challenge of sucrose. Sucrose absorption was estimated
by the appearance of increased levels of circulating glu-
cose after the sucrose challenge [6]. Data from two sepa-
rate studies found an 18% to 31% reduction in glucose
when taking LA-Cr supplement compared to ingesting
the sucrose alone. In the second study, we also found a
28% reduction in circulating insulin concentrations 60
minutes after taking the formulation. With regard to
safety, other than some discomfort with the capillary
measurements, no adverse effects were reported. Nor
were any adverse effects reported among the 10 subjects
Table 3 The 43-Panel Blood Chemistry Test Completed by
Subjects in Pilot Study, Phase-1
LIPID PANEL CBC (INCLUDES DIFF/PLT)
TRIGLYCERIDES WHITE BLOOD CELL COUNT






UREA NITROGEN (BUN) RDW
CREATININE PLATELET COUNT










BILIRUBIN, TOTAL OTHER MEASURES
ALKALINE PHOSPHATASE CARDIO CRP
AST & ALT TSH W/REFLEX TO FT4
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who consumed the LA-Cr daily for the 4-week study
period.
When the effects of the LA-Cr were measured weekly
with the acute oral sucrose challenge, the glucose-lower-
ing response of the combination remained over the 28-
day period. Additionally, there were no significant differ-
ences between baseline and ending values on any of the
43 blood chemistries, DXA body composition measures,
or the self-reported Quality of Life Inventory after using
the LA-Cr daily for 28 days.
We devised our protocol with the thought that we
were essentially examining the l-arabinose in the for-
mula. Findings similar to ours have been reported in a
well-controlled rat model, i.e., l-arabinose works quickly
when taken prior to a sucrose challenge and continues
to work effectively over a sub chronic period of time
that may provide insights into the mechanisms of action.
The data support the hypothesis that l-arabinose worked
by blocking sucrose absorption [6,13]. In rats, l-arabi-
nose did not influence circulating glucose levels when
Table 4 Capillary Glucose and Venous Insulin Levels After a 70 g Sucrose Challenge With and Without Simultaneous
Consumption of LA-Cr for the Pilot and Clinical Studies
Pilot Study N = 20 (Glucose Measurements Only)
Minutes from Baseline (glucose) :0 :30 :45 :60 :90
Mean glucose levels in the control group (sugar only) 100.4 157.9 161.3 151.4 121.5
Standard deviations of glucose in control group (sugar only) 16.1 23.8 18.5 24.7 17.0
Mean glucose levels in the treatment group 104.5 149.1 149.5 133.4 116.4
Standard deviations of glucose levels in treatment group 12.0 15.9 16.8 20.7 13.7
Clinical Study N = 50 (Glucose measurements)
Minutes from Baseline (glucose) :0 :30 :45 :60 :90
Mean glucose levels in the control group (sugar only) 97.2 150.3 151.4 141.8 120.5
Standard deviations of glucose in control group (sugar only) 10.3 22.2 25.0 25.6 22.2
Mean glucose levels in the treatment group 99.9 142.8 140.0 133.5 116.9
Standard deviations of glucose levels in treatment group 11.5 15.8 16.8 19.1 18.8
Clinical Study N = 49 Insulin measurements)
Minutes from Baseline (insulin) :0 :30 n/a :60 n/a
Mean insulin levels in the control group (sugar only) 4.4 32.3 32.2
Standard deviations of insulin in control group (sugar only) 3.9 24.7 19.9
Mean insulin levels in the treatment group 4.4 29.0 24.4
Standard deviations of insulin scores in thetreatment group 3.9 20.6 16.5
Table 5 Changes from Baseline in Capillary Glucose and Venous Insulin Levels After a 70 g Sucrose Challenge With
and Without Simultaneous Consumption of LA-Cr for Pilot Study (N = 20) and Clinical (N = 50)
Pilot Study N = 20 (Glucose Only)
Minutes from Baseline 30 45 60 90 AUC
% Difference Between Treatment vs Control -22.3% -26.0% -43.2% -43.5% -31.4%
Significance Levels P < 0.007 P < 0.001 P < 0.001 P < 0.031 P < 0.0001
Clinical Study N = 50 (Glucose Only)
Minutes from Baseline (Glucose) 30 45 60 90 AUC
% Difference Between Treatment vs Control -19.1% -26.1% -24.8% -27.1% -18.4%
Significance Levels P < 0.01 P < 0.001 P < 0.01 P < 0.05 P < 0.0001
Clinical Study N = 49 (Insulin Only)
Minutes from Baseline (Insulin) 30 60 AUC
% Difference Between Treatment vs Control -11.9% -28.3% -28.3%
Significance Levels NS P < 0.001 P < 0.01
P values are from repeated measures t-test and Ar
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no sucrose, but rather saline, was given. Under these cir-
cumstances, it did not lower glucose via enhancing
uptake or metabolism of glucose. Further, l-arabinose
did not affect glucose appearance when glucose replaced
sucrose as the challenging sugar. Finally, in vitro studies
have shown that l-arabinose blocks sucrase in an
uncompetitive manner [14].
This was unlike effects with chromium that influence
circulating glucose levels through an ability to enhance
insulin sensitivity and its removal from the circulation.
While chromium could have influenced the results of our
sub-chronic study, it is unlikely to have done so in the
acute studies since chromium does not work acutely after
initial intake [8-12]. Our studies examined the product
with both ingredients without partitioning the individual
or interactive effects of chromium and l-arabinose.
To explore individualized reactions, we examined the
association between suppression scores and baseline
measures by sub-grouping glucose and insulin suppres-
sion scores into four equal quartiles. An ANOVA
revealed that there were no statistically significant rela-
tionships between glucose suppression scores and base-
line measures of glucose, insulin, age, gender, ethnicity,
scale weight, height, bone mineral density, total body
fat, total body lean, and body mass index. However,
there was a significant association between glucose sup-
pression scores and % body fat (P = 0.038). A further
comparison of the quartiles of glucose suppression
scores and % body fat revealed that the greater the sup-
pression score, the lower the % body fat (Q4 = 32.5%,
Q3 = 40.8%, Q2 = 40.8%, Q1 = 42.5%). A Student t-test
between the highest (n = 12) and lowest (n = 12) glu-
cose suppression quartiles was also significant (P =
0.025). This could suggest that the higher the subject’s
% fat, the more LA-Cr may be required to obtain the
same glucose suppression results.
An ANOVA of the insulin suppression score quartiles
failed to reach statistical significance on any of the base-
line measures, including % body fat. However, a t-test
between the highest and lowest age quartiles (Q4 = 33.9
yrs, Q3 = 40.1 yrs, Q2 = 40.6 yrs, Q1 = 46.5 yrs)
revealed a significant relationship between age and insu-
lin suppression suggesting the insulin suppression effect
may be greatest in younger people. However, the irregu-
lar pattern of Q2-Q4 calls this interpretation into ques-
tion, suggesting it may be a statistical artifact as a
function of the multiple ANOVA analyses conducted.
The data from these two separate studies reveal that a
formula containing l-arabinose and chromium (LA-Cr)
can facilitate a consistent suppression of both circulating
glucose and insulin without adverse side effects. The
replication of the suppressive effect observed in the two
sequential studies increases the confidence of the formu-
la’s efficacy. Furthermore, the percentage of subjects for
whom the supplement had at least some suppressive
effect, 78% for glucose and 70% for insulin, is particu-
larly noteworthy since we had little control over how
many subjects actually fasted for the required 10 hours
prior to being tested.
There is a widespread belief that we are undergoing a
global “epidemic” of obesity and diabetes [14-16]. Some
studies have suggested that an important contributing
factor is the greater intake of rapidly absorbed or simple
carbohydrates, particularly sugar [17-19]. At least one
study [19] suggests that rapidly absorbed carbohydrates
are more harmful than those that are more slowly
absorbed, perhaps due to the difference in their effects
on the glucose-insulin system. The data derived from
this study suggest that it may be feasible to suppress the
harmful effects of glucose and insulin associated with
intake of rapid carbohydrates with a low- or no-risk
dietary supplement. Since even small reductions of cir-
culating glucose and insulin can have significant health
benefits, this study suggests that longer-term and dose-
related studies need to be conducted.
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